Indivior Pharmaceuticals Inc. Common Stock vs NEOS S&P 500 High Income ETF — how do they compare? Indivior Pharmaceuticals Inc. Common Stock trades at $34.01 (market cap $4.18B), while NEOS S&P 500 High Income ETF trades at $53.55 (market cap $12.59B). The key difference: NEOS S&P 500 High Income ETF is far larger — about 3× Indivior Pharmaceuticals Inc. Common Stock's market cap, and NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Indivior Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Indivior Pharmaceuticals Inc. Common Stock for 0 Days and NEOS S&P 500 High Income ETF for 59 Days on average.
| INDV | SPYI | |
|---|---|---|
Market Cap | $4.18B | $12.59B |
Volume | 1,819,746 | 1,834,804 |
Sector | Health | Income / Options Overlay |
52-Week High | $41.83 | $54.42 |
52-Week Low | $24.09 | $47.98 |
Typical Hold Time | 0 Days | 59 Days |
Enterprise Value | $4.47B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SPYI trades at $54.11 with minimal daily movement (+0.02%). Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. Recent news highlights SPYI's role in income-focused portfolios while raising concerns about principal erosion from covered call strategies. The ETF's dividend payments remain consistent with recent distributions around $0.53-0.54 per share.
The outlook for SPYI balances high income generation against capital preservation risks. While the covered call strategy provides attractive yields, investors face potential principal erosion during market rallies. Recent analyst coverage suggests a cautious approach given the trade-offs between income stability and growth limitations inherent in the fund's strategy.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Indivior Pharmaceuticals, Inc. is a pharmaceutical company focused on treatments for opioid use disorder and other addiction-related conditions, including its Suboxone film and tablet products.
Read more on INDV →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →